Alto Neuroscience (NYSE:ANRO) Trading Up 7.3% – Should You Buy?

Alto Neuroscience, Inc. (NYSE:ANRO)’s share price shot up 7.3% during trading on Wednesday . The stock traded as high as $22.09 and last traded at $22.4140. 13,949 shares changed hands during trading, a decline of 93% from the average session volume of 202,469 shares. The stock had previously closed at $20.88.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ANRO. Robert W. Baird upped their price target on Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Wall Street Zen raised shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. BTIG Research lifted their price target on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Finally, Chardan Capital upped their price objective on shares of Alto Neuroscience from $15.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus target price of $26.50.

Alto Neuroscience Stock Performance

The company has a current ratio of 15.42, a quick ratio of 15.42 and a debt-to-equity ratio of 0.20. The company has a market cap of $689.04 million, a price-to-earnings ratio of -9.74 and a beta of 2.52. The stock has a 50 day moving average price of $17.69 and a two-hundred day moving average price of $12.82.

Institutional Trading of Alto Neuroscience

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of Montreal Can bought a new stake in Alto Neuroscience in the second quarter valued at approximately $25,000. AlphaCore Capital LLC grew its holdings in shares of Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after buying an additional 10,000 shares during the period. AQR Capital Management LLC acquired a new position in shares of Alto Neuroscience in the 1st quarter valued at $52,000. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the 4th quarter valued at $62,000. Finally, Invesco Ltd. acquired a new stake in Alto Neuroscience during the 1st quarter worth $67,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.